AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - AbbVie reported revenue of $16.62 billion for the quarter ended December 2025, reflecting a 10% increase year-over-year and a surprise of +1.58% over the Zacks Consensus Estimate of $16.36 billion [1] - The earnings per share (EPS) for the quarter was $2.71, up from $2.16 in the same quarter last year, with an EPS surprise of +2.02% compared to the consensus estimate of $2.66 [1] Revenue Performance by Product - Humira's net revenue in the US was $897 million, significantly below the average estimate of $574.85 million, representing a year-over-year decline of -28% [4] - Internationally, Humira generated $349 million, slightly below the estimated $374.4 million, marking a -20% change year-over-year [4] - Oncology product Elahere reported $182 million, which was below the average estimate of $191.62 million but showed a +23% increase year-over-year [4] - Qulipta's international revenue reached $43 million, exceeding the estimate of $39.74 million, with a remarkable +186.7% year-over-year growth [4] - The Juvederm Collection generated $249 million, below the estimate of $272.17 million, reflecting a -10.8% year-over-year decline [4] - Vraylar's total revenue was $1.02 billion, surpassing the estimate of $994.67 million, with a +10.6% year-over-year increase [4] - Imbruvica's revenue was $671 million, below the average estimate of $714.9 million, showing a -20.9% year-over-year decline [4] - Eye Care products generated $580 million, slightly above the estimate of $568.88 million, with a -10.2% year-over-year change [4] - Botox Therapeutic revenue was $990 million, close to the estimate of $995.91 million, reflecting a +13.4% year-over-year increase [4] - Aesthetics revenue totaled $1.29 billion, slightly above the estimate of $1.28 billion, with a -0.9% year-over-year change [4] - Venclexta generated $710 million, below the estimate of $725.34 million, with an +8.4% year-over-year increase [4] - Neuroscience product Vyalev reported $183 million, exceeding the estimate of $170.15 million [4] Stock Performance - AbbVie shares returned +0.8% over the past month, compared to a +0.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]